AML |

Inhibitor outperforms rivals in leukemia, lymphoma

Published on April 20, 2018April 20, 2018 by HT Staff

Researchers in the lab
Photo by Rhoda Baer

Preclinical research suggests the pan-FLT3/pan-BTK inhibitor CG’806 is more effective than other kinase inhibitors in fighting certain hematologic malignancies. In one study, CG’806 proved more potent than comparator drugs in primary samples of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). In another study,... [Read Article]

Antibody has ‘potent’ effects against AML

Published on April 19, 2018April 19, 2018 by HT Staff

Micrograph showing AML
Image from Paulo
Henrique Orlandi Mourao

The bispecific antibody APVO436 has demonstrated robust T-cell activation with limited cytokine release in acute myeloid leukemia (AML), according to researchers. APVO436 binds CD123 and CD3 to redirect T-cell cytotoxicity against CD123-expressing tumor cells. Researchers found that APVO436 induced T-cell cytotoxicity in AML cells in... [Read Article]

Drug appears to aid chemo in AML

Published on April 14, 2018April 14, 2018 by HT Staff

Nurse bandaging
chemotherapy patient
Photo by Rhoda Baer

Adding an experimental compound to chemotherapy is a “promising” treatment approach for certain patients with acute myeloid leukemia (AML), according to researchers. They tested the compound, CPI-613, in combination with high-dose cytarabine and mitoxantrone in a phase 1 trial of patients with relapsed or refractory AML.... [Read Article]

Drug shows promise for treating AML, MDS

Published on April 12, 2018April 12, 2018 by HT Staff

Lab mouse

Preclinical results support clinical testing of an experimental agent in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), according to researchers. The agent, ALRN-6924, was shown to combat AML and MDS by restoring activity of the tumor-suppressing protein p53. ALRN-6924 exhibited antileukemic activity in AML cells and mouse models of the disease, as... [Read Article]

Gene variants linked to survival after HSCT

Published on April 11, 2018April 11, 2018 by HT Staff

DNA helix
Image by Spencer Phillips

New research has revealed a link between rare gene variants and survival after hematopoietic stem cell transplant (HSCT). Researchers performed exome sequencing in nearly 2500 HSCT recipients and their matched, unrelated donors. The sequencing revealed several gene variants—in both donors and recipients—that were significantly associated with overall survival... [Read Article]

Agent exhibits activity in leukemias, MDS

Published on April 4, 2018April 20, 2018 by HT Staff

AML cells

The experimental agent prexigebersen (formerly BP1001) was considered well-tolerated and demonstrated early evidence of activity against relapsed/refractory hematologic disorders in a phase 1/1b trial. The drug reduced blasts in the bone marrow and peripheral blood for patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS). When given... [Read Article]

Drug receives orphan designation for AML

Published on April 3, 2018April 2, 2018 by HT Staff

Micrograph showing AML
Image from Paulo
Henrique Orlandi Mourao

The US Food and Drug Administration (FDA) has granted orphan designation to MAX-40279 for the treatment of acute myeloid leukemia (AML). MAX-40279 is a multi-target kinase inhibitor being developed by MaxiNovel Pharmaceuticals, Inc. The drug mainly targets FMS-related tyrosine kinase 3 (FLT3) and fibroblast growth... [Read Article]

Leukemia research pioneer dies at 92

Published on March 27, 2018March 27, 2018 by HT Staff

James F. Holland, MD
Photo from the National
Library of Medicine

James F. Holland, MD, passed away last week, at the age of 92, due to complications of cardiovascular disease. Dr Holland has been called a pioneer in the field of leukemia research. He and his colleagues are credited with using combination chemotherapy to transform... [Read Article]

Manufactured graft deemed safe in blood cancer patients

Published on March 21, 2018March 21, 2018 by HT Staff

Peripheral blood
stem cell graft

Phase 1 results suggest a programmed cellular therapy is safe for use in patients with hematologic malignancies. The therapy, ProTmune, is being developed as a next-generation allogeneic graft intended to reduce the incidence and severity of acute graft-versus-host disease (GVHD) after hematopoietic stem cell transplant (HSCT). Three of 7... [Read Article]